CD274 and neoplasm: As in COAD immunotherapy, the combined therapy of nivolumab/lpilimumab can effectively control the progression of microsatellite instability-high COAD (47); triptolide can suppress the infiltration of macrophages in the TME and participate in the regulation of tumor cell growth and apoptosis of COAD (48); romidepsin can promote the expression of PD-L1 in COAD, and change the state of anti-tumor immune responses in vivo (49).